Pilon A, Vaubourdolle M, Peta V, Valla D, Castera L, Bedossa P, Ratziu V, Deckmyn O, Poynard T; the QuidNash Consortium

Actions du personnel

Les fichiers sont réservés à un usage autorisé dans les canaux partenaires BioPredictive.

Key publication Fibrotest Actitest Article Our Group

Citation

Pilon A, Vaubourdolle M, Peta V, Valla D, Castera L, Bedossa P, Ratziu V, Deckmyn O, Poynard T; the QuidNash Consortium.

Tests

Maladies du foie

Atteintes hépatiques

Comparaisons

Thèmes

Profils de patients

Panier

Votre panier est vide.

Parcourez les publications et utilisez Ajouter au panier sur n'importe quelle page de détail pour constituer une archive ZIP à envoyer aux clients.

Parcourir les publications

Pilon A, Vaubourdolle M, Peta V, Valla D, Castera L, Bedossa P, Ratziu V, Deckmyn O, Poynard T; the QuidNash Consortium

Sur le même sujet

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).